Altria delivered solid Q2 2026 results with 2.8% adjusted EPS growth, narrowed and raised the low end of full-year guidance, and highlighted moderating cigarette industry declines. Management emphasized progress in the smoke-free portfolio, particularly On Plus expansion, and a more constructive FDA enforcement posture toward regulated e-vapor and nicotine pouch products. Adjusted diluted EPS was $1.48 in Q2 and $2.80 in the first half, up 2.8% and 4.9% respectively.
Buzzberg readFull-year EPS guidance raised at lower endAltria delivered solid Q2 2026 results with 2.8% adjusted EPS growth, narrowed and raised the low end of full-year guidance, and highlighted moderating cigarette industry declines. Management emphasized progress in the smoke-free portfolio, particularly On Plus expansion, and a more constructive FDA enforcement posture toward regulated e-vapor and nicotine pouch products. Adjusted diluted EPS was $1.48 in Q2 and $2.80 in the first half, up 2.8% and 4.9% respectively.Read full analysisCollapse analysis
Altria delivered solid Q2 2026 results with 2.8% adjusted EPS growth, narrowed and raised the low end of full-year guidance, and highlighted moderating cigarette industry declines. Management emphasized progress in the smoke-free portfolio, particularly On Plus expansion, and a more constructive FDA enforcement posture toward regulated e-vapor and nicotine pouch products. Adjusted diluted EPS was $1.48 in Q2 and $2.80 in the first half, up 2.8% and 4.9% respectively.
FY2026 EPS guidance was raised at the low end to $5.61-$5.72, implying 3.5%-5.5% growth.
PMUSA total retail share grew, with Marlboro premium share stable and Basic gaining targeted share in discount outlets.
On Plus expanded to ~120,000 stores and drove sequential share gains despite tough 2025 comparisons.
Revenue$6.111B
+13% QoQ
EPS$1.48
+12% QoQ
Gross margin74.86%
reported
Op margin51.32%
reported
What changed this quarter
01
Guidance
Full-year EPS guidance raised at lower end
Guidance tone
02
Smoke-free
OnPlus expansions and new flavors planned for 2026
Adjusted diluted EPS was $1.48 in Q2 and $2.80 in the first half, up 2.8% and 4.9% respectively.
03
Regulatory
FDA enforcement guidance seen as positive for launches
FY2026 EPS guidance was raised at the low end to $5.61-$5.72, implying 3.5%-5.5% growth.
04
E-vapor
Altria plans to re-enter e-vapor market with NJOY Ace
PMUSA total retail share grew, with Marlboro premium share stable and Basic gaining targeted share in discount outlets.
Demand
Demand
Bookings & conversion
Cigarette volume declines moderating on illicit e-vapor enforcement. Management expressed confidence in first-half execution and narrowed guidance, but repeatedly flagged ongoing consumer financial pressure and competitive/regulatory uncertainty.
Tone · Measured
Management expressed confidence in first-half execution and narrowed guidance, but repeatedly flagged ongoing consumer financial pressure and competitive/regulatory uncertainty.
Supply-chain alpha
A1
ABI equity earnings grew 21.5% y/y to $158M in Q2, far outpacing Altria's own EPS growth, implying BUD's beer margins/mix are recovering faster than headline industry trends suggest.
ABI equity earnings grew 21.5% y/y to $158M in Q2, far outpacing Altria's own EPS growth, implying BUD's beer margins/mix are recovering faster than headline industry trends suggest. — For a pure financial stake this is a direct read-through to BUD momentum and supports Altria's capital returns via higher investment income.
… half oil tobacco product segment volumes declined by approximately 2% and 5.5% respectively. Oral tobacco product segment retail share was 29% for the second quarter and for the first half. Retail share was stable sequentially, reflecting the growth of on and resiliency of our MSP brands. In the highly profitable moist smokeless tobacco segment, Copenhagen continued to maintain its longstanding premium leadership. Turning to ABI's financial results, We recorded $158 million in adjusted equity earnings in the second quarter, up 21.5% versus the prior year. We continue to view our ABI stake as a financial investment, and our goal remains to maximize the long-term value of the investment for our shareholders. We remain committed to returning significant value to shareholders. During the first half of the year, We paid approximately $3.6 billion in dividends and repurchased 5.3 million shares for $335 million. At the end of the second quarter, we had $665 million remaining under our current share repurchase program, which expires at the end of the year. In addition, our balance sheet remains strong. Our debt-to-EBITDA ratio as of June 30th was 1.9 times in line with our target of …
🍪 Cookies
We use cookies to operate this site and for analytics. Declining won't affect your access to content.